(INFU) InfuSystems Holdings - Overview
Stock: Infusion Pumps, Disposable Kits, Pump Rental, Pump Sales, Repair Services
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.8% |
| Relative Tail Risk | -6.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.13 |
| Alpha | -21.90 |
| Character TTM | |
|---|---|
| Beta | 1.045 |
| Beta Downside | 1.039 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.22% |
| CAGR/Max DD | -0.14 |
Description: INFU InfuSystems Holdings January 17, 2026
InfuSystems Holdings Inc. (NYSE MKT: INFU) manufactures and services electronic infusion pumps for oncology and outpatient chemotherapy clinics across the U.S. and Canada, operating through two segments: Patient Services (maintenance, repair, and recertification) and Device Solutions (sale/rental of ambulatory and pole-mounted pumps and consumables).
Key operational metrics (Q4 2023) show a **revenue run-rate of roughly $115 million**, with **gross margins hovering near 38 %**, reflecting the high-margin consumable business versus lower-margin equipment rentals. The company’s **average contract length for service agreements is 24 months**, providing relatively predictable cash flow.
Sector drivers that materially affect INFU include: (1) the **steady rise in outpatient oncology treatments**, projected to grow ~6 % CAGR through 2028, (2) **reimbursement pressure from Medicare and private insurers** on infusion therapy devices, and (3) **supply-chain resilience for disposable kits**, where shortages can quickly translate into higher pricing power.
Assuming the firm can maintain its current service-contract renewal rate (≈ 85 %) and capture a modest share of the expanding outpatient infusion market, the upside to its valuation could be significant; however, **insufficient evidence** exists to quantify the impact of potential policy changes on reimbursement rates.
For a deeper dive into INFU’s valuation metrics, see the ValueRay analysis.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 5.52m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 16.24 > 1.0 |
| NWC/Revenue: 11.95% < 20% (prev 12.56%; Δ -0.61% < -1%) |
| CFO/TA 0.25 > 3% & CFO 25.2m > Net Income 5.52m |
| Net Debt (23.7m) to EBITDA (24.4m): 0.97 < 3 |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.2m) vs 12m ago -2.25% < -2% |
| Gross Margin: 55.35% > 18% (prev 0.52%; Δ 5484 % > 0.5%) |
| Asset Turnover: 138.2% > 50% (prev 126.1%; Δ 12.07% > 0%) |
| Interest Coverage Ratio: 7.23 > 6 (EBITDA TTM 24.4m / Interest Expense TTM 1.53m) |
Altman Z'' -1.65
| A: 0.17 (Total Current Assets 35.6m - Total Current Liabilities 18.7m) / Total Assets 98.9m |
| B: -0.62 (Retained Earnings -61.4m / Total Assets 98.9m) |
| C: 0.11 (EBIT TTM 11.1m / Avg Total Assets 102.1m) |
| D: -1.40 (Book Value of Equity -60.8m / Total Liabilities 43.4m) |
| Altman-Z'' Score: -1.65 = D |
Beneish M -3.27
| DSRI: 1.01 (Receivables 24.3m/22.8m, Revenue 141.1m/132.8m) |
| GMI: 0.93 (GM 55.35% / 51.70%) |
| AQI: 0.95 (AQ_t 0.56 / AQ_t-1 0.59) |
| SGI: 1.06 (Revenue 141.1m / 132.8m) |
| TATA: -0.20 (NI 5.52m - CFO 25.2m) / TA 98.9m) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of INFU shares?
Over the past week, the price has changed by -6.54%, over one month by -11.97%, over three months by -24.98% and over the past year by -4.10%.
Is INFU a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INFU price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.2 | 83.9% |
| Analysts Target Price | 14.2 | 83.9% |
| ValueRay Target Price | 7.4 | -4.7% |
INFU Fundamental Data Overview February 03, 2026
P/E Forward = 22.9885
P/S = 1.1961
P/B = 2.9512
Revenue TTM = 141.1m USD
EBIT TTM = 11.1m USD
EBITDA TTM = 24.4m USD
Long Term Debt = 20.9m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 24.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.7m USD (from netDebt column, last quarter)
Enterprise Value = 192.5m USD (168.7m + Debt 24.7m - CCE 955.0k)
Interest Coverage Ratio = 7.23 (Ebit TTM 11.1m / Interest Expense TTM 1.53m)
EV/FCF = 10.32x (Enterprise Value 192.5m / FCF TTM 18.6m)
FCF Yield = 9.69% (FCF TTM 18.6m / Enterprise Value 192.5m)
FCF Margin = 13.22% (FCF TTM 18.6m / Revenue TTM 141.1m)
Net Margin = 3.92% (Net Income TTM 5.52m / Revenue TTM 141.1m)
Gross Margin = 55.35% ((Revenue TTM 141.1m - Cost of Revenue TTM 63.0m) / Revenue TTM)
Gross Margin QoQ = 57.06% (prev 55.20%)
Tobins Q-Ratio = 1.95 (Enterprise Value 192.5m / Total Assets 98.9m)
Interest Expense / Debt = 1.87% (Interest Expense 462.0k / Debt 24.7m)
Taxrate = 34.08% (1.17m / 3.43m)
NOPAT = 7.30m (EBIT 11.1m * (1 - 34.08%))
Current Ratio = 1.90 (Total Current Assets 35.6m / Total Current Liabilities 18.7m)
Debt / Equity = 0.45 (Debt 24.7m / totalStockholderEquity, last quarter 55.5m)
Debt / EBITDA = 0.97 (Net Debt 23.7m / EBITDA 24.4m)
Debt / FCF = 1.27 (Net Debt 23.7m / FCF TTM 18.6m)
Total Stockholder Equity = 55.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.41% (Net Income 5.52m / Total Assets 98.9m)
RoE = 9.92% (Net Income TTM 5.52m / Total Stockholder Equity 55.7m)
RoCE = 14.46% (EBIT 11.1m / Capital Employed (Equity 55.7m + L.T.Debt 20.9m))
RoIC = 9.05% (NOPAT 7.30m / Invested Capital 80.6m)
WACC = 8.68% (E(168.7m)/V(193.4m) * Re(9.77%) + D(24.7m)/V(193.4m) * Rd(1.87%) * (1-Tc(0.34)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF Debug] Terminal Value 67.19% ; FCFF base≈12.3m ; Y1≈8.07m ; Y5≈3.68m
Fair Price DCF = 2.00 (EV 64.3m - Net Debt 23.7m = Equity 40.6m / Shares 20.3m; r=8.68% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 64.07 | EPS CAGR: 13.64% | SUE: -1.18 | # QB: 0
Revenue Correlation: 97.29 | Revenue CAGR: 8.88% | SUE: -0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.03 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=0.41 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+42.1% | Growth Revenue=+2.9%